Denali Therapeutics DNLI
NASDAQ DNLI
$19.85 -0.48 (-2.36%)
At close: Nov 10, 2026 · 4:00 PM EST

Denali Therapeutics (DNLI) Change in Receivables (2026)

Updated

Denali Therapeutics (DNLI) recorded Change in Receivables of $14.96 million in Q3 2026.

Analysis

Denali Therapeutics (DNLI) Change in Receivables (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change Receivables (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn -
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn -188.00 Mn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn -312.00 Mn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn -
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 108.00 Mn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn -52.00 Mn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn -
10 Denali Therapeutics 3.83 Bn 743.92 Mn 17.59 Mn 14.96 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 14.96 Mn
API Access

Denali Therapeutics Change in Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=change-in-receivables&ticker=DNLI&period=max&api_key=YOUR_API_KEY